Risedronate
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Risedronate is a nitrogen-containing bisphosphonate used for the treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis, male osteoporosis, and Paget's disease. The VERT and HIP trials demonstrated significant fracture risk reduction. It is available in daily, weekly, and monthly dosing formulations.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Risedronate is a nitrogen-containing bisphosphonate used for the treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis, male osteoporosis, and Paget's disease. NutriStack rates the supporting evidence as strong. Common adult dosing is 5 mg daily, 35 mg once weekly, or 150 mg once monthly; Paget's: 30 mg daily for 2 months (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete calcium. This profile indexes 10 sources.
- GI upset (abdominal pain, dyspepsia, nausea)
- Esophageal irritation
- Musculoskeletal pain
- Esophageal abnormalities that delay emptying
- Inability to stand or sit upright for 30 minutes
The bottom line
Evidence rating strong. Most-documented uses: reduces vertebral fracture risk by 41–49% (vert trials), reduces non-vertebral fracture risk by 39%, hip fracture reduction in elderly women (hip trial). 10 sources indexed (2007–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Binds to bone hydroxyapatite at sites of active remodeling and is internalized by osteoclasts during bone resorption. Inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast cytoskeletal organization and function, reducing bone resorption. This leads to positive bone remodeling balance and increased bone mineral density.2,3
Dosing & protocol.
Immediate-release: Take first thing in the morning on empty stomach with 6–8 oz plain water. Remain upright 30 minutes. Delayed-release (Atelvia): Take immediately after breakfast. Do not crush or chew.
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Calcium
ModerateBisphosphonate suppression of bone resorption can lower serum calcium, especially when calcium intake, vitamin D status, or kidney function is poor.
Full safety detail.
Side effects
- GI upset (abdominal pain, dyspepsia, nausea)
- Esophageal irritation
- Musculoskeletal pain
- Headache
- Osteonecrosis of the jaw (rare)
- Atypical femoral fractures (rare, long-term use)
- Hypocalcemia
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
3- 1Adverse Gastrointestinal Effects of Alendronate Versus Risedronate in Osteoporosis: A Systematic Review and Meta-analysisPMIDNouh MI, Albuti H, Hasosah M et al. · Annals of African medicine · 2026
Nouh MI, Albuti H, Hasosah M et al.. Adverse Gastrointestinal Effects of Alendronate Versus Risedronate in Osteoporosis: A Systematic Review and Meta-analysis. Annals of African medicine. 2026
- 2Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: A systematic review and meta-analysisPMIDWang M, Wang L, Ye R · International journal of surgery (London, England) · 2018
Wang M, Wang L, Ye R. Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: A systematic review and meta-analysis. International journal of surgery (London, England). 2018
- 3Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysisPMIDLi Q, Xu B · Journal of orthopaedic surgery and research · 2018
Li Q, Xu B. Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis. Journal of orthopaedic surgery and research. 2018
Randomized controlled trials
1- 4Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trialPMIDBlay R, Flores LE, Kupzyk K et al. · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
Blay R, Flores LE, Kupzyk K et al.. Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2024
Reviews & position papers
2- 5Safety and effectiveness of risedronate in Paget's disease of bone: postmarketing surveillance study in JapanPMIDHashimoto J, Arai Y, Kurosu S et al. · Journal of bone and mineral metabolism · 2024
Hashimoto J, Arai Y, Kurosu S et al.. Safety and effectiveness of risedronate in Paget's disease of bone: postmarketing surveillance study in Japan. Journal of bone and mineral metabolism. 2024
- 6Review of the safety and efficacy of risedronate for the treatment of male osteoporosisPMIDBobba R, Adachi JD · Clinical interventions in aging · 2007
Bobba R, Adachi JD. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clinical interventions in aging. 2007
Reference material
4- 7Harris ST et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial (VERT-NA). JAMA. 1999;282(14):1344-1352.Source linkedPMID
- 8McClung MR et al. Effect of risedronate on the risk of hip fracture in elderly women (HIP). N Engl J Med. 2001;344(5):333-340.Source linkedPMID
- 9Chai SJ et al. The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis. Front Endocrinol (Lausanne). 2025.Source linkedPMID
- 10Goa KL, Balfour JA. Risedronate. Drugs & aging. 1998Source linkedPMID
Common questions.
Quick answers about Risedronate, drawn from the data on this page.
What is Risedronate?
Risedronate is a nitrogen-containing bisphosphonate used for the treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis, male osteoporosis, and Paget's disease. The VERT and HIP trials demonstrated significant fracture risk reduction. It is available in daily, weekly, and monthly dosing formulations.
What is Risedronate used for?
Commonly cited benefits of Risedronate include: Reduces vertebral fracture risk by 41–49% (VERT trials); Reduces non-vertebral fracture risk by 39%; Hip fracture reduction in elderly women (HIP trial); Available as once-weekly or once-monthly dosing; Effective in glucocorticoid-induced osteoporosis. NutriStack rates the overall evidence as strong.
What is a typical dose of Risedronate?
A typical adult dose of Risedronate is 5 mg daily, 35 mg once weekly, or 150 mg once monthly; Paget's: 30 mg daily for 2 months (as prescribed by your physician). The commonly recommended form is Oral tablet; delayed-release (Atelvia) is taken after breakfast. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Risedronate?
Reported side effects include gi upset (abdominal pain, dyspepsia, nausea), esophageal irritation, musculoskeletal pain, headache, osteonecrosis of the jaw (rare), atypical femoral fractures (rare, long-term use). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Risedronate?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Risedronate in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.